Dr. Muin J. Khoury recently retired from the CDC after a 40-year public health career, including 26 years leading the Office of Public Health Genomics, which he formed in 1998. He contributed to the ...

The European Health Data Space Regulation has arrived but will its mandatory sharing requirement be its tour de force or Achilles’ heel? The Regulation amounts to an ambitious and laudable step ...

In the current outbreak, the UK government has designated certain groups of people as ‘extremely vulnerable’ to severe illness due to underlying health conditions, requiring the highest possible ...

These plans have been a long time in the making. The intention to produce a strategy ‘to ensure the UK is able to offer a predictive, preventative and personalised health and care service for people ...

Widely regarded as a founder of cell free DNA (cfDNA) technology, Professor Dennis Lo is now pioneering investigation into the emerging science of fragmentomics. If you were at were at our recent ...

The rapid development, approval and roll out of multiple vaccines against SARS-CoV-2, the virus that causes COVID-19, is an impressive achievement for science and healthcare. The virus genome was ...

Cost-utility studies provide critical information for the costs and benefits of using any new test, typically building on existing public health and screening programmes, within a defined population.

The UK government has launched a new alliance to sequence the genomes of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. Backed by a £20 million investment, the COVID-19 Genomics ...

Polygenic scores aim to measure the cumulative effect of multiple genetic variants to make predictions about a person’s health. The most likely areas of potential use are in risk prediction, including ...

The UK is a global leader in genomics, but should perhaps look to its laurels as other countries increase their focus and capability in this area. The Hong Kong government recently announced a new ...

A recent consultation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) indicates a welcome new direction for public and patient involvement (PPI). The MHRA proposed new five-year ...